(RTTNews) - Biotechnology company Innate Pharma S.A (IPHA) on Tuesday revealed first-quarter revenue of 1.2 million euros, down from last year's 6.6 million euros
On the Nasdaq, the stock was down 3 percent on Monday's afterhours at $2.3200.
During the three-month period, Innate Pharma said that cash, cash equivalents and financial assets amounted to 72.5 million euros as of March 31. First-quarter financial liabilities amounted to 29.2 million euros, the company added.
Innate Pharma said that Sanofi has announced a 15 million euros investment in the company, further strengthening its ongoing partnership, which includes the development of the BCMA-targeting ANKET program for autoimmune indications.
The company said that the FDA has granted a Breakthrough Therapy Designation to lacutamab for the treatment of relapsed or refractory Sézary syndrome. Long-term follow-up data from the TELLOMAK Phase 2 trial will be presented at the ASCO Annual Meeting this year, Innate Pharma added.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
